Skip to main content
. 2022 Feb 17;2022:5952296. doi: 10.1155/2022/5952296

Figure 2.

Figure 2

(a) ROC of 2D clinical, radiomics, and nomogram models to differentiate benign from malignant ovarian tumors. (b) ROC of 3D clinical, radiomics, and nomogram models to differentiate benign from malignant ovarian tumors. (c) AUC of 2D and 3D nomogram models to differentiate benign from malignant ovarian tumors (P < 0.05).